• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

Novartis AG ADR NVS 2 Star

Last Price$89.84Day Change (%)0.12%
Open Price$89.79Day Change ($)0.11
Day Range89.51–89.9952-Week Range72.24–91.66

As of Fri 08/29/2014 04:31 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

    Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

  2. Ipsen: 2014 Half-Year Results and 2014 Objectives

    Ipsen: 2014 Half-Year Results and 2014 Objectives

  3. Where Are the Opportunities in U.S. Health Care?

    As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.

  4. A Shift in Health-Care M&A Activity

    Recent deals have been driven more by tax strategies than therapeutic synergies.

  5. Managing Expectations, Part II

    On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...

  6. Looking for Bubbles Part One: A Statistical Approach

    Novartis NVS announced Friday that it is removing Zelnorm for irritable bowel syndrome from the U.S. market at the request of the Food and Drug Administration. We think Zelnorm could eventually return to pharmacy shelves in the United States, but we have drastically reduced our estimate of sales ...

  7. Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company

    Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company

  8. Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition

    Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.